<DOC>
	<DOCNO>NCT01366365</DOCNO>
	<brief_summary>This double-blind , randomize , two-cohort , placebo-controlled , parallel group study characterized pharmacokinetics , safety , tolerability MNTX follow single dos steady-state multiple dosing assessed effect age pharmacokinetics , safety tolerability MNTX .</brief_summary>
	<brief_title>Study Pharmacokinetics , Safety Tolerability Intravenous Methylnaltrexone Bromide</brief_title>
	<detailed_description />
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<mesh_term>Methylnaltrexone</mesh_term>
	<criteria>1 . Healthy Males female age 18 45 year healthy male females 65 year age old . 2 . Subjects nonsmokers 3 . Subjects body weight within range 70100 kg ( 154220 lb ) . 1 . Subjects previously expose MNTX 2 . Subjects history vasovagal episode faint within past five year 3 . Subjects history psychiatric neurologic disorder 4 . Subjects history narrowangle glaucoma intraocular hypertension 5 . Subjects test positive hepatitis B surface antigen , IgM hepatitis B core antibody , hepatitis C antibody , HIV 6 . Subjects diagnosis alcohol substance dependence .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>